{"id":"NCT04440163","sponsor":"Pfizer","briefTitle":"MenABCWY Noninferiority Study in Healthy Participants ≥10 to <26 Years of Age","officialTitle":"A PHASE 3, RANDOMIZED, ACTIVE-CONTROLLED, OBSERVER-BLINDED TRIAL TO ASSESS THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF MenABCWY IN HEALTHY PARTICIPANTS ≥10 TO <26 YEARS OF AGE","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-06-17","primaryCompletion":"2022-07-24","completion":"2022-07-24","firstPosted":"2020-06-19","resultsPosted":"2023-04-18","lastUpdate":"2023-04-18"},"enrollment":2431,"design":{"allocation":"RANDOMIZED","model":"FACTORIAL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Meningococcal Vaccine"],"interventions":[{"type":"BIOLOGICAL","name":"MenABCWY","otherNames":[]},{"type":"BIOLOGICAL","name":"Saline","otherNames":[]},{"type":"BIOLOGICAL","name":"Trumenba","otherNames":[]},{"type":"BIOLOGICAL","name":"MenACWY-CRM","otherNames":[]}],"arms":[{"label":"1-Immuno Subset (ACWY Naive,MenABCWY/Saline)","type":"EXPERIMENTAL"},{"label":"2-Immuno Subset (ACWY Naive, Trumenba/MenACWY-CRM)","type":"EXPERIMENTAL"},{"label":"3-Immuno Subset (ACWY Experienced,MenABCWY/Saline)","type":"EXPERIMENTAL"},{"label":"4-Immuno Subset (ACWY Experienced,Trumenba/MenACWY-CRM)","type":"EXPERIMENTAL"},{"label":"5-Safety Subset (ACWY Naive,MenABCWY/Saline)","type":"EXPERIMENTAL"},{"label":"6-Safety Subset (ACWY Naive,Trumenba/MenACWY-CRM)","type":"EXPERIMENTAL"},{"label":"7-Safety Subset (ACWY Experienced,MenABCWY/Saline)","type":"EXPERIMENTAL"},{"label":"8-Safety Subset (ACWY Experienced,Trumenba/MenACWY-CRM)","type":"EXPERIMENTAL"}],"summary":"The aim of this study is to determine the immunologic noninferiority of MenABCWY to licensed vaccines Trumenba and MenACWY-CRM (Menveo) by assessing the safety and immunogenicity of MenABCWY and the comparators in both ACWY-naïve and ACWY-experienced healthy participants ≥10 to \\<26 years of age.","primaryOutcome":{"measure":"Percentage of Participants Achieving At Least 4-Fold Rise in Serum Bactericidal Assay Using Human Complement (hSBA) Titer From Baseline for Each MenACWY Strains: 1 Month After Vaccination 2 in Group 1 Compared to 1 Month After Vaccination 1 in Group 2","timeFrame":"Baseline (pre-vaccination on Day 1), 1 month after Vaccination 2 in Group 1 and 1 month after Vaccination 1 in Group 2","effectByArm":[{"arm":"ACWY-Naive: Group 1 MenABCWY + Saline (Immunogenicity and Safety Set)","deltaMin":97.8,"sd":null},{"arm":"ACWY-Naive: Group 2 Trumenba+ MenACWY - CRM (Immunogenicity and Safety Set)","deltaMin":95.3,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"10 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":5,"exclusionCount":8},"locations":{"siteCount":78,"countries":["United States","Czechia","Denmark","Hungary","Poland"]},"refs":{"pmids":[],"seeAlso":["https://pmiform.com/clinical-trial-info-request?StudyID=C3511001"]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":547},"commonTop":["Injection site pain (PAIN AT INJECTION SITE)","Fatigue (FATIGUE)","Headache (HEADACHE)","Myalgia (MUSCLE PAIN)","Swelling (SWELLING)"]}}